芪龙祛瘀合剂治疗亚型心绞痛临床效应的比较研究

Comparative study on Clinical Effect of Qilong Quju Composition Treating Subtype Angina

[目的]探讨心绞痛有效治疗方法。[方法]以芪龙祛瘀合荆治疗亚型心绞痛患者51例，并与相同例数的阳性对照组做临床疗效比较研究。[结果]给药前2组患者血浆内皮素（ET-1）、血小板膜表面受体（CD62P）明显高于健康人（P〈0．05），P物质（SP神经肽）明显低于健康人（P〈0．05）；给药后2组患者临床积分，ET-1、CD62P显著下降（P〈0．05～0．01），ST段、SP显著升高（P〈0．05～0．01），治疗组临床积分，ST段、ET-1、CD62P、SP改善幅度明显优于对照组（P〈0．05）。[结论]亚型心绞痛患者ET-1、CD62P、SP明显异常，芪龙祛瘀合剂既改善临床积分，又抑制ET-1、CD62P释放，升高血浆SP，从而具有良好临床疗效。

[Objective]To observe the efficacy of clearing stasis composition of QILONG in treating the 51 patients with subtype angina, and to compare the clinical therapeutic effects between the therapeutic group （QILONG group） and the comparison group. [Results] It suggests that the ET-1, CD62P of two groups were obviously higher than those of the healthy group（P〈0.05）, P materia （SP） was obviously lower than that of the healthy group（P〈0. 05）before treatment. The improvement extant of clinical accumulation, ST segment, ET-1,CD62P and SP was obviously better than those of the comparison group（P〈0. 05）after treatment. [Conclusion] It suggests that the ET-1, CD62P and SP of the patients with subtype angina are obviously abnormal, and the clearing stasis composition of QILONG could not only improve the clinical accumulation, but also restraint the release of ET-1, CD62P and improve SP level in plasma. Therefore, the clearing stasis composition of QILONG presents better clinical therapeutic effect.